Promising new agents in oncologic treatment

Sridhar Mani, Mark J. Ratain

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Over the past year, several new anticancer agents have entered the clinic and are undergoing further phase II clinical development at the time of this writing. There has been a sudden influx of rationally designed drugs with novel therapeutic effects ranging from direct cellular toxicity to inhibition of blood vessel formation and of metastases. This review focuses only on cytotoxic drugs that have been in clinical development for the past 5 years; however, only recently have these drugs found a 'niche' in the clinic. These drugs include novel taxanes (eg, docetaxel), the camptothecin analogues (eg, irinotecan [CPT-11]), the newer generation of thymidylate synthase inhibitors (eg, raltitrexed [ZD 1694, Tomudex]), nocleoside analogues (eg, gemcitabine), and oral alternatives to intravenous 5-fluorouracil. Most of these agents have completed or have entered phase II or III testing, and the results of these trials will be available to us over the next few years.

Original languageEnglish (US)
Pages (from-to)525-534
Number of pages10
JournalCurrent Opinion in Oncology
Volume8
Issue number6
StatePublished - 1996
Externally publishedYes

Fingerprint

irinotecan
docetaxel
gemcitabine
Pharmaceutical Preparations
Taxoids
Camptothecin
Thymidylate Synthase
Therapeutic Uses
Fluorouracil
Antineoplastic Agents
Blood Vessels
Neoplasm Metastasis
raltitrexed

ASJC Scopus subject areas

  • Cancer Research

Cite this

Promising new agents in oncologic treatment. / Mani, Sridhar; Ratain, Mark J.

In: Current Opinion in Oncology, Vol. 8, No. 6, 1996, p. 525-534.

Research output: Contribution to journalArticle

Mani, S & Ratain, MJ 1996, 'Promising new agents in oncologic treatment', Current Opinion in Oncology, vol. 8, no. 6, pp. 525-534.
Mani, Sridhar ; Ratain, Mark J. / Promising new agents in oncologic treatment. In: Current Opinion in Oncology. 1996 ; Vol. 8, No. 6. pp. 525-534.
@article{b6d6289569de4fb1a0bceb3d8a5e680a,
title = "Promising new agents in oncologic treatment",
abstract = "Over the past year, several new anticancer agents have entered the clinic and are undergoing further phase II clinical development at the time of this writing. There has been a sudden influx of rationally designed drugs with novel therapeutic effects ranging from direct cellular toxicity to inhibition of blood vessel formation and of metastases. This review focuses only on cytotoxic drugs that have been in clinical development for the past 5 years; however, only recently have these drugs found a 'niche' in the clinic. These drugs include novel taxanes (eg, docetaxel), the camptothecin analogues (eg, irinotecan [CPT-11]), the newer generation of thymidylate synthase inhibitors (eg, raltitrexed [ZD 1694, Tomudex]), nocleoside analogues (eg, gemcitabine), and oral alternatives to intravenous 5-fluorouracil. Most of these agents have completed or have entered phase II or III testing, and the results of these trials will be available to us over the next few years.",
author = "Sridhar Mani and Ratain, {Mark J.}",
year = "1996",
language = "English (US)",
volume = "8",
pages = "525--534",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Promising new agents in oncologic treatment

AU - Mani, Sridhar

AU - Ratain, Mark J.

PY - 1996

Y1 - 1996

N2 - Over the past year, several new anticancer agents have entered the clinic and are undergoing further phase II clinical development at the time of this writing. There has been a sudden influx of rationally designed drugs with novel therapeutic effects ranging from direct cellular toxicity to inhibition of blood vessel formation and of metastases. This review focuses only on cytotoxic drugs that have been in clinical development for the past 5 years; however, only recently have these drugs found a 'niche' in the clinic. These drugs include novel taxanes (eg, docetaxel), the camptothecin analogues (eg, irinotecan [CPT-11]), the newer generation of thymidylate synthase inhibitors (eg, raltitrexed [ZD 1694, Tomudex]), nocleoside analogues (eg, gemcitabine), and oral alternatives to intravenous 5-fluorouracil. Most of these agents have completed or have entered phase II or III testing, and the results of these trials will be available to us over the next few years.

AB - Over the past year, several new anticancer agents have entered the clinic and are undergoing further phase II clinical development at the time of this writing. There has been a sudden influx of rationally designed drugs with novel therapeutic effects ranging from direct cellular toxicity to inhibition of blood vessel formation and of metastases. This review focuses only on cytotoxic drugs that have been in clinical development for the past 5 years; however, only recently have these drugs found a 'niche' in the clinic. These drugs include novel taxanes (eg, docetaxel), the camptothecin analogues (eg, irinotecan [CPT-11]), the newer generation of thymidylate synthase inhibitors (eg, raltitrexed [ZD 1694, Tomudex]), nocleoside analogues (eg, gemcitabine), and oral alternatives to intravenous 5-fluorouracil. Most of these agents have completed or have entered phase II or III testing, and the results of these trials will be available to us over the next few years.

UR - http://www.scopus.com/inward/record.url?scp=0029902488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029902488&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 525

EP - 534

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 6

ER -